Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes

Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes


Luspatercept is being developed as part of the global collaboration between Acceleron and Celgene. "These positive data presented in lower-risk MDS confirm our optimism in new opportunities for luspatercept beyond our ongoing Phase 3 trials," said Michael Pehl, President, Hematology and Oncology for Celgene.



from Biotech News